Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 11

recruiting
3 968
countries
28
conditions
2 103

264 trials match your criteria

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Malignant peritoneal neoplasm+2

Not yet recruiting

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib

Triple negative breast cancer

Not yet recruiting

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Colorectal cancer

Not yet recruiting

Conversion intraperitoneal chemotherapy with oxaliplatin plus drug combination in colorectal cancer with peritoneal metastases unsuitable for upfront surgery or HIPEC

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Non-small cell lung cancer

Not yet recruiting

Safety and efficacy of rilvegostomig with drug combination in adult patients with unresectable stage III non‑small cell lung cancer undergoing chemoradiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Ovarian cancer

Not yet recruiting

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Interstitial lung disease+2

Not yet recruiting

Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Lung cancer metastatic

Not yet recruiting

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer

Not yet recruiting

Study of cemiplimab with or without chemotherapy for non-small cell lung cancer patients with high PD-L1 levels to reduce rapid disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Non-small cell lung cancer metastatic

Not yet recruiting

Study of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Breast neoplasm

Not yet recruiting

Study of oral TherO2-01S22 with anti-HER2 therapy in patients with metastatic breast cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Breast cancer female

Not yet recruiting

Monitoring the Effects of Epirubicin, Cyclophosphamide, and Docetaxel in Women with Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.